CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.

Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...

TUESDAY, June 24, 2025 (HealthDay News) — A single infusion of a new stem cell-based treatment may have helped 10 out of 12 ...

A study may have found a cure for type 1 diabetes. Here, experts explain how the treatment, zimislecel, works and what it ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

"This edition of the Healthcare Enforcement column discusses two judicial decisions from recent months relating to the ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...